• Zentalis Pharmaceuticals Inc ZNTL.OQ reported a quarterly adjusted loss of 37 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.24. The mean expectation of nine analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -97 cents to -43 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Zentalis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 37 cents​.

• The company reported a quarterly loss of $26.87 million.

• Zentalis Pharmaceuticals Inc shares had risen by 19.0% this quarter and lost 54.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.4% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.00, about 72.4% above its last closing price of $1.38

This summary was machine generated from LSEG data August 7 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)